Merkel cell polyomavirus–negative Merkel cell carcinoma is associated with JAK‐STAT and MEK‐ERK pathway activation
Open Access
- 1 November 2021
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 251-260
Abstract
Merkel cell polyomavirus (MCPyV) is monoclonally integrated into the genomes of approximately 80% of Merkel cell carcinomas (MCCs). While the presence of MCPyV affects the clinicopathological features of MCC, the molecular mechanisms of MCC pathogenesis after MCPyV infection are unclear. This study investigates the association between MCPyV infection and activation of the MEK‐ERK and JAK‐STAT signaling pathways in MCC to identify new molecular targets for MCC treatment. The clinicopathological characteristics of 30 MCPyV‐positive and 20 MCPyV‐negative MCC cases were analyzed. The phosphorylation status of MEK, ERK, JAK, and STAT was determined by immunohistochemical analysis. The activation status of the MEK‐ERK and JAK‐STAT pathways and the effects of a JAK inhibitor (ruxolitinib) was analyzed in MCC cell lines. Immunohistochemically, the expression of pJAK2 (P = .038) and pERK1/2 (P = .019) was significantly higher in MCPyV‐negative than in MCPyV‐positive MCCs. Male gender (hazard ratio [HR] 2.882, P = .039), older age (HR 1.137, P < .001), negative MCPyV status (HR 0.324, P = .013), and advanced cancer stage (HR 2.672, P = .041) were identified as unfavorable prognostic factors; however, the phosphorylation states of JAK2, STAT3, MEK1/2, and ERK1/2 were unrelated to the prognosis. The inhibition of cell proliferation by ruxolitinib was greater in MCPyV‐negative MCC cell lines than in an MCPyV‐positive MCC cell line. The expression of pERK1/2 and pMEK was higher in MCPyV‐negative than in MCPyV‐positive cell lines. These results suggest that activation of the JAK2 and MEK‐ERK pathways was more prevalent in MCPyV‐negative than in MCPyV‐positive MCC and the JAK inhibitor ruxolitinib inhibited MEK‐ERK pathway activation. Consequently, the JAK‐STAT and MEK‐ERK signaling pathways may be potential targets for MCPyV‐negative MCC treatment.Keywords
Funding Information
- Japan Society for the Promotion of Science (26460433 [K.H.], 26860238 [M.M.] ; 17K15644 [M.M.], 17K08720 [K.H.], 21K06885 [M.M.])
This publication has 37 references indexed in Scilit:
- Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus–positive and Merkel cell polyomavirus–negative carcinomasHuman Pathology, 2015
- Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinomaLaboratory Investigation, 2014
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase InhibitorsClinical Cancer Research, 2014
- Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosisInternational Journal of Cancer, 2012
- Targeting the Interleukin-6/Jak/Stat Pathway in Human MalignanciesJournal of Clinical Oncology, 2012
- Activation of PI3K Signaling in Merkel Cell CarcinomaClinical Cancer Research, 2012
- Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell CarcinomaClinical Cancer Research, 2011
- Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcomeInternational Journal of Cancer, 2010
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell CarcinomaJournal of Investigative Dermatology, 2006